Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropanicant - Suven Life Sciences

Next Previous
Search
Drug Profile

Ropanicant - Suven Life Sciences

Alternative Names: SUVN-911

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suven Life Sciences
  • Class Antidepressants; Aza compounds; Cyclohexanes; Cyclopropanes; Heterocyclic bicyclo compounds; Pyridines; Small molecules
  • Mechanism of Action Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 20 Feb 2025 Suven Life Sciences plans a phase IIb trial for Major depressive disorder in USA (PO, Tablet, bid), in April 2025 , (NCT06836063)
  • 05 Feb 2024 Suven Life Sciences completes a phase II clinical trials in Major depressive disorder in USA (PO) (NCT06126497)
  • 20 Jan 2024 Phase-II clinical trials in Major depressive disorder in USA (PO) (NCT06126497)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top